TAP Block Study
[STUDY_ID_REMOVED]
IRB Approval Date:  07AUG2023
Bariatric  Exparel  TAP Block  Study  Date:  8/4/2023 
1 Study  Title:  Single Blinded  Randomized  Trial  of Transversus Abdominis Plane Block  Using  
Liposomal Bupivacaine in  Metabolic  and Bariatric Surgery  Patients  
Principal  Investigator: Selwan  Barbat  
Co-Investigators: Paul  Chandler, Elizabeth  Santone  
Sponsor  or funding  source:  Wake Forest  University  Health  Sciences  
Background,  Rationale, and Context 
The tra nsversus abdominis plane (TAP) block was  described  in 2007 using an ultrasound 
to inject  local  anesthetic between  the internal oblique and  transversus  abdominis muscles  where 
the sensory nerves  of the abdominal wall  travel  [1]. The TAP  block can  also be performed  by the 
surgeon with  laparoscopic guidance. TAP  block has  been  shown to  provide analgesia after  ab-
dominal surgery, decreasing  opioid use,  and is widely  accepted  into practice [2].  TAP  block has  
become a cornerstone in  enhanced  recovery  after surgery  programs,  as well  as part of multi-
modal analgesia,  and opioid reducing efforts  nationwide. A recent  meta -analysis  of Randomized  
Controlled Trials  (RCT)  comparing TAP  block with  bupivacaine or ropivacaine to  no TAP  block 
in bariatric  surgery  showed reduced  postoperative nausea and  vomiting  and time  to ambulation  
[3]. Liposomal bupivacaine compared  to plain  bupivacaine has  been  touted to provide a longer 
duration of analgesia (up  to 72 hours) by slowly  releasing  the anesthetic agent into  local  tissue.  A 
recent  systematic  review  comparing liposomal bupivacaine to  conventional local  anesthetic 
agents  in regional anesthesia,  including TAP  blocks, showed conflicting  results  so no definitive  
conclusions could be made [4].  It is unclear  if liposomal bupivacaine is  superior to  plain  bupiva-
caine for TAP  blocks in  bariatric  surgery.  Our study would be the first  RCT  comparing laparo-
scopic TAP  block with  liposomal bupivacaine vs plain  bupivacaine in  a bariatric  surgery  popula-
tion.  
Objectives  
Compared  to only B upivacaine administered  via TAP  block, we  will investigate  the anal-
gesia effects  to patients  undergoing metabolic  and bariatric  surgery  receiving  TAP  block with  a 
Liposomal Bupivacaine mixture.      
Primary  Objective : To determine  if patients  undergoing metabolic  and bariatric  surgery  
receiving  TAP  block with  a Liposomal Bupivacaine results  in pain  scores,  as measured  by visual 
analogic scale (VAS),  that are equivalent  compared  to patients  receiving  TAP  block with  Bupi-
vacaine only.  
Primary  Hypothesis: 
1)Lower  values  of the outcome variable VAS  are desirable,  and the hypothesis
is listed  below â€“
Bariatric  Exparel  TAP Block  Study  Date:  8/4/2023 
2 Hypothesis 1. 1  
ğ»ğ»0:  ğœ‡ğœ‡ ğ¸ğ¸âˆ’ğœ‡ğœ‡ğ‘†ğ‘†  â‰¥ ğ›¿ğ›¿  (Study group is  different  compared  to the active 
control group      by ğ›¿ğ›¿ or more)  
ğ»ğ»1:  ğœ‡ğœ‡ ğ¸ğ¸âˆ’ğœ‡ğœ‡ğ‘†ğ‘†  <ğ›¿ğ›¿ (Study group is  equivalent to  the active control when  
difference is  within  prespecified  ğ›¿ğ›¿) 
Where ğœ‡ğœ‡ğ¸ğ¸, ğœ‡ğœ‡ğ‘†ğ‘†  are the population means for the outcome VAS  measured  at 24 
hours after  surgery  for the study group (E) and the standard (S) active group, re-
spectively  ğ›¿ğ›¿ is non- inferiority  margin,  specified  in advance based  on clinical  judgement. 
Based  on our clinical  experience,  ğ›¿ğ›¿ = 1.5 
Secondary  Objectives:  Compared  to TAP  block with  Bupivacaine only, we  will compare 
opioid consumption, and  other effect  differences  to patients  undergoing metabolic  and bariatric 
surgery  receiving  TAP  block with  Liposomal Bupivacaine.      
Secondary  Hypotheses 
Hypothesis 2.1 â€“ Patients  undergoing metabolic  and bariatric  surgery  receiving  
TAP  block with  Liposomal Bupivacaine results  in less opioid consumption before  hospi-
tal discharge /during the first 48 hours postoperatively as  measured  in morphine equiva-
lents  (mg) compared  to patients  receiving  simply  TAP  block with  Bupivacaine only.  
Hypothesis 2.2 - Patients  undergoing metabolic  and bariatric  surgery  receiving  
TAP  block with  Liposomal Bupivacaine results  in pain  score as measured  by visual ana-
logic scale (VAS) at  12 hours after  surgery  that are equivalent compared  to patients  re-
ceiving  TAP  block with  Bupivacaine only.  
Exploratory objectives : We will explore other effects,  including pain  score  at 48 hours, 
and 72 hours after  surgery, total opioid consumption required  post op during their  one- week  post 
op visit as  measured  in morphine equivalences.  
Methods  and Measures  
Design  
This st udy is  a 2-arm parallel  single blinded randomized  equivalency, single- cen-
ter, clinical  trial.   Patients  will be blinded to  type of TAP  block used.  
Setting  
This st udy will take place at  Atrium Health,  an academic medical  center.  
Subjects  selection  criteria  
Bariatric  Exparel  TAP Block  Study    Date:  8/4/2023 
3 Inclusion  Criteria  
To be eligible  for enrollment in  this study, participants  must meet  all the following 
criteria:  
1. Adult, age > 18 years  
2. Participants  who  can give written  informed  consent and  willing  to comply with all 
stud- related  procedures.  
3. Patients  undergoing primary  sleeve gastrectomy  or roux- en-y gastric  bypass 
Exclusion Criteria  
1. Patients  undergoing duodenal switch  procedures 
2. Patients  undergoing concomitant hiatal  hernia repair  or ventral  hernia repair  or 
cholecystectomy  at time  of primary  metabolic  surgery 
3. Patients  with  chronic opioid use 
Sample  Size 
The number of patients  required  in each  group is  determined  from  a power analysis  based  
on primary  hypothesis.  
In this study, based  on our clinical  experience,  we assume  standard  deviation  for each  
group is  3, the margin  of equivalence is  1.5 on NRS,  and the true  difference  between  the two  
groups is  0 on the NRS.  Group sample  size of  88 from  each  group achieves  90% power to  detect  
our prespecified  equivalence margins, with  alpha of 0.05.  Assuming a 20% dropout or with-
drawal  based  upon previous experience,  106 subjects  per group will be required.    
 
Interventions  and Interactions  
 There will be two  groups: (1) active control and  (2) study group. Active  control group pa-
tients  receive TAP  block with  a Bupivacaine only mixture,  containing 50 mL  0.5% Bupivacaine,  
and 100 mL  normal saline  solution. Study group patients  will receive TAP  block with  a Liposo-
mal Bupivacaine mixture,  containing 20 mL  Liposomal Bupivacaine,  30 mL  0.5% Bupivacaine,  
and 100 mL  normal saline  solution. TAP  block technique will be standardized  using subcostal as  
well as anterior  axillary  line as  landmarks, injecting  down to  level  of T10, using laparoscopic-
guided approach. TAP  block will be administered  at the start  of every  case,  after the first port is  
placed  upon laparoscopy. Type of anesthesia administered  will also  be standardized  including 
the use of narcotics,  lidocaine,  inhalational anesthesia and  Ketamine.  
 Randomization schedules will be generated  by SAS  9.4 (SAS  Institute  Inc., Cary,  NC)  by 
using a masked  block randomization  procedure. Eligible  patients  will be randomized  with  a 1:1 
ratio between  the 2 groups of patients  receiving  TAP  block Exparel  mixture  or simply  bupiva-
caine administered  via TAP  block. Research  Electronic Data Capture (REDCap)  randomization 
Bariatric  Exparel  TAP Block  Study    Date:  8/4/2023 
4 module will be used  to manage randomization and  allocate treatment groups. The  allocation  se-
quence will be concealed  with  application  of the REDCap.   
 
Outcome Measure(s)  
Primary  Outcome measures  
1. Pain score at  24 hours post- operative,  using visual analogue scale (VAS),  ranging 
from  1 to 10. One  indicates  no pain, and  10 indicates  the worst  pain  one could  image.  
Secondary  Outcome Measures  
1. Pain scores  at 12 hours, 48  hours, and  72 hours post-operatively.  
2. Morphine milligram equivalences  consumed during hospital stay  
3. Morphine milligram equivalences  prescribed  and consumed as  measured  at one week  
follow up clinic  visit 
4. Post-operative nausea and  vomiting  (PONV)  measured  by a numerical  score (1:  no 
nausea or vomiting, 2: some nausea no vomiting, 3: nausea and  vomiting) 
5. Length of stay  in hours 
6. Patient  satisfaction  score  
These parameters  will be scored  via SeamlessMD  on a phone application, as  well  as pa-
per and pen on a standardized  reporting  form  for patients  less comfortable using technology. 
Data will also  be collected  from  patient  electronic  charts.   
 
Analytical Plan  
 Equivalency test  with  priori  specified  non- inferiority  region will be used  to assess pri-
mary  outcome variables.  
Descriptive  statistics  (mean,  range,  percentage,  median, etc.)  will be used  to assess the quality  
and accuracy  of the administrative  and clinical  data.  Means  with  standard deviations or medians  
with interquartile  range (IQR) will be reported  for continuous variables  and percentages  for cate-
gorical  variables.  Missing  data will be evaluated  prior to  data modeling. General  linear  regres-
sion, or other generalized  linear  regression  models will be used  to compare the outcomes be-
tween  the two  groups with  both univariate or multivariate  analyses.  Potential confounders will be 
identified  with  univariate analysis.  For univariate analyses,  a Studentâ€™s t- test or Wilcoxon two -
sample  test will be used  for continuous variables,  and chi-square test  for categorical  variables  
against  the primary  and secondary  outcomes. Both unadjusted and  adjusted  odds ratio  (OR) with  
Bariatric  Exparel  TAP Block  Study    Date:  8/4/2023 
5 corresponding 95% confidence interval  (CI)  will be  reported. Two -tailed  p values  will be calcu-
lated  for all  tests,  and p< 0.05 is  considered  statistically  significant.  All data  will be analyzed  us-
ing Statistical Analysis Software,  version  9.4 (SAS  Institute  Inc., Cary,  NC).  
There are no plans for interim data analyses.  Analyses  will be conducted according to  per-proto-
col (PP)  principle. 
 
Human  Subjects  Protection  
Subject  Recruitment  Methods  
Patients  who  are scheduled  for sleeve gastrectomy  or roux- en-y gastric  bypass will be identified  
and recruited  for the  study at  the Atrium Health  Weight Management  clinics  during their  pre-
operative visit.  The bariatric  surgeons and  bariatric surgery  fellows  will do the recruiting, and  pa-
tients  will be contacted  directly  face to  face during the preoperative visit about the study. Patients  
will also  receive a written  flyer  containing information about the study during the preoperative 
visit.  As all qualifying patients  will be informed  about the study during the preoperative visit,  ac-
cess to participation  among  women  and minorities  will depend on how many  of these patients  
undergo sleeve gastrectomy  or roux- en-y gastric  bypass at  our institution.  Subjectâ€™s  privacy  will 
be protected  by storing records  of Protected  Health  Information  in locked  facilities  or password 
protected  computers. Data will be stored  on a password  protected  computer of the investigator 
and in a password protected  RedCap  database.  
 
Informed  Consent  
Signed informed  consent will be obtained from  each  subject.  The investigators as  well  as the 
other bariatric surgeons and bariatric  surgery  fellows  will obtain informed  consent at  the Atrium 
Health  Weight  Management  clinics  during the preoperative visit.  
 
Confidentiality  and Privacy  
Confidentiality  will be protected  by collecting  only information  needed  to assess study out-
comes,  minimizing  to the fullest extent  possible the collection  of any  information  that could di-
rectly  identify  subjects,  and maintaining  all study information in  a secure manner.  To help  ensure 
subject  privacy  and confidentiality, only a unique study identifier  will appear  on the data collec-
tion form.  Any  collected  patient  identifying information  corresponding to  the unique study iden-
tifier  will be maintained  on a linkage file,  store  separately  from  the data.  The linkage file  will be 
kept secure,  with  access  limited  to designated  study personnel. Following data collection  subject  
identifying information  will be destroyed (state  the anticipated  time  the data will be destroyed, 
e.g. three years  after closure of the study, and  the method of destruction), consistent with  data 
validation  and study design, producing an  anonymous analytical  data set.  Data access  will be 
limited  to study staff.  Data and  records  will be kept locked  and secured,  with  any computer data 
Bariatric  Exparel  TAP Block  Study    Date:  8/4/2023 
6 password protected. No  reference to  any individual participant  will appear  in reports,  presenta-
tions, or publications that  may  arise from  the study. 
 
Data  and Safety  Monitoring  
The principal investigator  will be responsible for the overall  monitoring of the data and  safety  of 
study participants.  The principal investigator will be assisted  by other members  of the study staff.  
 
Reporting  of Unanticipated Problems,  Adverse  Events  or Deviations 
Any unanticipated  problems, serious and  unexpected adverse events,  deviations or protocol 
changes  will be promptly reported  by the principal  investigator or designated member  of the re-
search  team  to the IRB and sponsor or appropriate government agency  if appropriate. 
 
References:  
1. McDonnell JG,  Oâ€™Donnell  BD,  Farrell  T, et al. Transversus abdominis plane block: a cadav-
eric and  radiological evaluation.  Reg Anesth  Pain  Med.  2007;32:399â€“404  
2. Mukhtar K,  Singh S.  Transversus abdominis plane block for laparoscopic  surgery. Br  J 
Anaesth.  2009;102:143â€“4.  
3. Hytham K.S.  Hamid,  Amjed  Y. Ahmed, Alan  A. Saber,  Sameh  H. Emile,  Mohamed  Ibrahim,  
Jaime  Ruiz-Tovar. Transversus abdominis plane block  using a short- acting  local  anesthetic re-
duces  pain  and opioid consumption after  laparoscopic bariatric  surgery:  a meta -analysis,  Surgery  
for Obesity  and Related  Diseases.  Volume 16, Issue  9. 2020, Pages  1349-1357  
4. Jin  Z, Ding  O, Islam  A, Li R, Lin J. Comparison of liposomal bupivacaine and  conventional 
local  anesthetic agents  in regional anesthesia:  A systematic  review.  Anesth  and Analg. 2021; 132 
(6): 1626-34. 
 
Appendix  
1. Consent form  
2. Copy of Seamless  MD Daily  Health  Check  surveys  
  
 
 
Bariatric  Exparel  TAP Block  Study    Date:  8/4/2023 
7  
 